Zobrazeno 1 - 10
of 941
pro vyhledávání: ''
Autor:
Hong Luo, Yi Hu, Patricia Keegan, Hongqian Guo, Ji-Yan Liu, Haige Chen, Sheng Yao, Weifeng Wang, Jun Guo, Fangjian Zhou, Xudong Yao, Benkang Shi, Zhigang Ji, Hui Feng, Xinan Sheng, Zhisong He, Bin Hu, Ziling Liu, Jin Wu, Xin Yao, Jinhai Fan, Yiran Huang
Publikováno v:
Clinical Cancer Research. 28:489-497
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety, efficacy
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Alvin M. Matsumoto, Nima Sharifi, Michael T. Schweizer, Heather H. Cheng, R. Bruce Montgomery, Mary-Ellen Taplin, P.W. Kantoff, Felix S. Chew, Evan Y. Yu, Orpheus Kolokythas, Steven P. Balk, Peter S. Nelson, Brett T. Marck, Elahe A. Mostaghel
Publikováno v:
Clin Cancer Res
Purpose: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens prior to starting abiraterone acetate (AA) is associated with more rapid progression. We evaluated the effect of AA on androgens in castration-resistant prostate
Autor:
Konstantin Penkov, Taofeek K. Owonikoko, Peter M. Ellis, Bruce A. Bach, Anne Sibille, Vasudha Sehgal, Choon Hee Son, Lei He, Jaimee Glasgow, Harry J.M. Groen, Junya Fujimoto, Patricia M. de Groot, Kingston Kang, Martin Dunbar, Lauren Averett Byers, Steven J. M. Gans, Dmitry Bentsion
Publikováno v:
Clinical Cancer Research, 27(14), 3884-3895. AMER ASSOC CANCER RESEARCH
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients and Methods: Patients were randomi
Autor:
Amy E. DeZern, Alan F. List, Jeffrey E. Lancet, Hannah Newman, Eric Padron, Maria E. Balasis, Mikkael A. Sekeres, Rami S. Komrokji, Anthony M. Hunter, Qianxing Mo, Traci Kruer, Sandrine Niyongere, Markus Ball, Christopher Letson, Aaron T. Gerds, Gail J. Roboz, David A. Sallman, Hailing Zhang, Onyee Chan, David P. Steensma, William Dominguez-Viqueira
Publikováno v:
Clinical Cancer Research. 27:6095-6105
Purpose: Chronic myelomonocytic leukemia (CMML) is a rare leukemia characterized by peripheral monocytosis with no disease-modifying therapies. CMML cells are uniquely hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) and ro
Autor:
Gang An, Chenmu Du, Shu Cheng, Jianfeng Zhou, Binghao Wu, Haiyi Guo, Lingzhi Yan, Liye Zhong, Yiling Yu, Jie Jin, Liping Xie, Jinhua Zhong, Daobin Zhou, Jianyong Li, Keshu Zhou, Lugui Qiu
Publikováno v:
Clinical Cancer Research. 27:5492-5501
Purpose: Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data in Asian populations are scarce. This trial is the first to investigate the effect of a BTK inhi
Autor:
Michael Fulkerson, Jeffrey A. Cadeddu, Sydney Haldeman, Roy Elias, Qurratulain Yousuf, Qing Yuan, Vitaly Margulis, Alana Christie, Ananth J. Madhuranthakam, Robert C. Sibley, DK Dwivedi, James Brugarolas, Payal Kapur, Asghar Hajibeigi, Ze Zhang, Junyu Guo, Aditya Bagrodia, Matthew A. Lewis, Yin Xi, Tiffani McKenzie, Allison Joyce, Hollis Notgrass, Ivan Pedrosa, Tao Wang, Durga Udayakumar, Alberto Diaz de Leon, Renée M. McKay
Publikováno v:
Clin Cancer Res
Purpose: Intratumoral heterogeneity (ITH) challenges the molecular characterization of clear cell renal cell carcinoma (ccRCC) and is a confounding factor for therapy selection. Most approaches to evaluate ITH are limited by two-dimensional ex vivo t
Autor:
Bose Kochupurakkal, Courtney Gannon, Adrienne de Jonge, Jean-Bernard Lazaro, Sarah Kelland, Khanh T. Do, Jennifer Hedglin, Alan D. D'Andrea, Allison Powers, Kalindi Parmar, Loan Vuong, Nicholas Quinn, Geoffrey I. Shapiro
Publikováno v:
Clinical Cancer Research. 27:4710-4716
Purpose:Checkpoint kinase 1 (CHK1) plays a central role in the response to replication stress through modulation of cell-cycle checkpoints and homologous recombination (HR) repair. In BRCA-deficient cancers with de novo or acquired PARP inhibitor res
Autor:
Vinod P. Balachandran, James J. Harding, Andrea Cercek, Michael I. D’Angelica, William R. Jarnagin, Louise Catherine Connell, Joshua S. Jolissaint, T. Peter Kingham, Kevin C. Soares, Kenneth Seier, Mithat Gonen, Nancy E. Kemeny, Ramyasree Madupuri, Ritika Kundra, Alice C. Wei, Thomas Boerner, Jeffrey A. Drebin, Carlie S. Sigel, Paul Shin, Efsevia Vakiani
Publikováno v:
Clin Cancer Res
Purpose: Lymph node metastasis (LNM) drastically reduces survival after resection of intrahepatic cholangiocarcinoma (IHC). Optimal treatment is ill defined, and it is unclear whether tumor mutational profiling can support treatment decisions. Experi
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Autor:
Rachel E. Sanborn, John E. Leonard, Crystal Mallow, Megan Ann Baumgart, Andreas Schröder, Nashat Y. Gabrail, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer, Nagashree Seetharamu, JT Beck, Michael Shafique, Elizabeth E. Evans, Desa Rae Pastore, Ramaswamy Govindan, Ernest S. Smith, Kevin M. Chin, Yanyan Lou, Terrence L. Fisher, Vikas Mishra, Alexander I. Spira
Publikováno v:
Clinical Cancer Research. 27:3630-3640
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune su